Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03BQP
|
|||
| Former ID |
DNC001200
|
|||
| Drug Name |
Rebamipide
|
|||
| Synonyms |
rebamipide; 90098-04-7; Mucosta; Proamipide; 111911-87-6; OPC-12759; Rebamipidum; Pramipide; Rebamipide [INN:JAN]; Rebamipidum [INN-Latin]; Rebamipida [INN-Spanish]; OPC 12759; CCRIS 3585; Rebamipide hydrate; 2-(4-Chlorobenzoylamino)-3-(1,2-dihydro-2-oxo-4-quinolyl)propionic acid; 139344-42-6; 2-[(4-chlorobenzoyl)amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid; Mucosta hydrate; NCGC00095161-01; Proamipide hydrate; 2-(4-Chlorobenzamido)-3-[2(1H)-quinolinon-4-yl]propionic Acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Peptic ulcer [ICD-11: DA61] | Phase 3 | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H15ClN2O4
|
|||
| Canonical SMILES |
C1=CC=C2C(=C1)C(=CC(=O)N2)CC(C(=O)O)NC(=O)C3=CC=C(C=C3)Cl
|
|||
| InChI |
1S/C19H15ClN2O4/c20-13-7-5-11(6-8-13)18(24)22-16(19(25)26)9-12-10-17(23)21-15-4-2-1-3-14(12)15/h1-8,10,16H,9H2,(H,21,23)(H,22,24)(H,25,26)
|
|||
| InChIKey |
ALLWOAVDORUJLA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 90098-04-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
5392994, 7848184, 8153104, 11372977, 11483873, 11487855, 11491774, 12013207, 14877402, 26612890, 26680453, 26749027, 26749028, 29224113, 48328567, 50043069, 50043070, 53787206, 57322578, 74747436, 85175212, 85788525, 88277041, 91011744, 92124604, 92309229, 92713511, 99582548, 104308112, 117664455, 117772935, 118842287, 124637454, 124891853, 124971198, 125275481, 125307349, 125312449, 125325998, 125337900, 125810026, 126617864, 126624745, 126640517, 126663153, 126683520, 127423927, 131294612, 131329793, 131784276
|
|||
| ChEBI ID |
CHEBI:93814
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides dorei DSM 17855
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Rebamipide can be metabolized by Bacteroides dorei DSM 17855 (log2FC = -0.852; p = 0.004). | |||
|
Studied Microbe: Bacteroides fragilis HMW 610
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Rebamipide can be metabolized by Bacteroides fragilis HMW 610 (log2FC = -0.759; p = 0.037). | |||
|
Studied Microbe: Bacteroides fragilis HMW 615
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Rebamipide can be metabolized by Bacteroides fragilis HMW 615 (log2FC = -0.767; p = 0.01). | |||
|
Studied Microbe: Bacteroides fragilis str. 3397 T10
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Rebamipide can be metabolized by Bacteroides fragilis str. 3397 T10 (log2FC = -0.529; p = 0.019). | |||
|
Studied Microbe: Bacteroides ovatus ATCC 8483
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Rebamipide can be metabolized by Bacteroides ovatus ATCC 8483 (log2FC = -0.444; p = 0.047). | |||
|
Studied Microbe: Bacteroides stercoris ATCC 43183
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Rebamipide can be metabolized by Bacteroides stercoris ATCC 43183 (log2FC = -0.455; p = 0.031). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron 7330
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Rebamipide can be metabolized by Bacteroides thetaiotaomicron 7330 (log2FC = -0.72; p = 0.011). | |||
|
Studied Microbe: Bacteroides uniformis ATCC 8492
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Rebamipide can be metabolized by Bacteroides uniformis ATCC 8492 (log2FC = -1.069; p = 0.012). | |||
|
Studied Microbe: Bacteroides xylanisolvens DSM18836
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Rebamipide can be metabolized by Bacteroides xylanisolvens DSM18836 (log2FC = -0.737; p = 0.004). | |||
|
Studied Microbe: Parabacteroides distasonis ATCC 8503
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Rebamipide can be metabolized by Parabacteroides distasonis ATCC 8503 (log2FC = -0.426; p = 0.018). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium ruminantium
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Rebamipide can be metabolized by Bifidobacterium ruminantium (log2FC = -0.52; p = 0.031). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | N-formyl peptide receptor (FPR1) | Target Info | Antagonist | [4] |
| KEGG Pathway | Rap1 signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Staphylococcus aureus infection | ||||
| NetPath Pathway | Leptin Signaling Pathway | |||
| Panther Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
| Reactome | G alpha (i) signalling events | |||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Human Complement System | ||||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 871). | |||
| REF 2 | The roles of prostaglandin E receptor subtypes in the cytoprotective action of prostaglandin E2 in rat stomach. Aliment Pharmacol Ther. 2000 Apr;14 Suppl 1:116-24. | |||
| REF 3 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 4 | Rebamipide suppresses formyl-methionyl-leucyl-phenylalanine (fMLP)-induced superoxide production by inhibiting fMLP-receptor binding in human neutrophils. J Pharmacol Exp Ther. 2001 Apr;297(1):388-94. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.